Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report

Article Medicine, General & Internal

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Zhihao Lu et al.

Summary: This study evaluated the efficacy of sintilimab in combination with chemotherapy for patients with unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. The results demonstrated significant improvements in overall survival and progression free survival with sintilimab plus cisplatin and paclitaxel compared to placebo plus chemotherapy. Similar benefits were seen with sintilimab plus cisplatin and 5-fluorouracil.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Oncology

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Haiping Jiang et al.

Summary: This study evaluated the efficacy of sintilimab plus CapeOx as a neoadjuvant regimen for patients with advanced resectable G/GEJ adenocarcinoma. The results showed a promising pathological complete response rate and good safety profile, suggesting that this combination regimen could be a new option for patients with locally advanced, resectable G/GEJ adenocarcinoma.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma

Audrey Melin et al.

Summary: Granulomatosis triggered by immune checkpoint inhibitors (ICI) is a common side effect in melanoma and other cancer patients. This study investigates the characteristics of this reaction, its relationship with sarcoidosis, its potential mechanisms, and its association with response to immunotherapy.

CANCERS (2022)

Add to Collection

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental